Renal denervation system

A renal denervation system is the equipment used for renal denervation: an ablation catheter for the renal arteries and the console that powers it. FDA files these catheters under one product code, QYI, in class 3, and defines them as for denervating the renal nerves to lower blood pressure. Two systems received US premarket approval in November 2023: an ultrasound system (P220023, approved 7 November 2023) and a radiofrequency system (P220026, approved 17 November 2023). Their original approval orders, the only ones read (later supplements were not), state the same indication: to reduce blood pressure as an adjunctive treatment in people with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This page records no study of benefit or harm.

Also called Renal denervation catheter · Ablation catheter, renal denervation

  • Technology
  • In this atlas

Overview

Technical summary

FDA product code QYI (Ablation Catheter, Renal Denervation), class 3, is an exact match; the openFDA record gives no regulation number. Approval facts are read from the original orders only: P220023 (Paradise Ultrasound Renal Denervation System; Recor Medical, Inc.; APPR 2023-11-07) and P220026 (Symplicity Spyral Multi-Electrode Renal Denervation Catheter with the Symplicity G3 RF Generator; Medtronic, Inc.; APPR 2023-11-17). Later supplements were not read. No MeSH descriptor was found. The procedure has its own page.

How it works

A catheter that denervates the renal nerves to lower blood pressure (FDA classification definition).

Limitations

  • The sources read are one FDA classification record, two original FDA approval orders and a narrative review; they state a definition, indications and the authors' view, and no study result is recorded on this page.
  • Each approval statement covers its own system only, and later supplements were not read.

Required infrastructure

  • The approval order for P220026 names a radiofrequency generator as part of the system.

Claims and evidence

Context Patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure, as the US approval orders of two renal denervation systems state

Recipient
Recipient not specified
Population
Patients with hypertension whose blood pressure is not adequately controlled by lifestyle modifications and antihypertensive medications, as the two approval orders word it. The statements read give no age group.
Care setting
Renal denervation system used as an adjunctive treatment (the orders' words)
Geography
United States (FDA premarket approval records)
Life stage
Not stated in the statements read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (regulatory statements)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Hypertension that lifestyle modifications and antihypertensive medications do not adequately control
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    Two premarket approvals under product code QYI state an indication for renal denervation systems. The openFDA record of P220023 (Recor Medical, Inc., decision APPR, 7 November 2023) says the Paradise Ultrasound Renal Denervation System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. The openFDA record of P220026 (Medtronic, Inc., decision APPR, 17 November 2023) says the Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.

    Applies to Recipient not specified Patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure, as the US approval orders of two renal denervation systems state

    Certainty method
    Not assessed
    Limitations
    This claim covers the two original approval orders only. Each approval has later supplements in openFDA; they were not read and may change the wording, the devices or the conditions of use. An FDA approval is a decision about a device, not a finding about how well it works. The orders do not use the term resistant hypertension. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (14)
    1. Supports FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read. · PMA: P220023

      Locator
      results[0].pma_number
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-07
      Source state
      Current
      Version fingerprint
      5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    2. Supports FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read. · PMA: P220023

      Locator
      results[0].applicant
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-07
      Source state
      Current
      Version fingerprint
      5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    3. Supports FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read. · PMA: P220023

      Locator
      results[0].decision_date
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-07
      Source state
      Current
      Version fingerprint
      5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    4. Supports FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read. · PMA: P220023

      Locator
      results[0].decision_code
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-07
      Source state
      Current
      Version fingerprint
      5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    5. Supports FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read. · PMA: P220023

      Locator
      results[0].product_code
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-07
      Source state
      Current
      Version fingerprint
      5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    6. Supports FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read. · PMA: P220023

      Locator
      results[0].ao_statement, fragment 1 of 2
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-07
      Source state
      Current
      Version fingerprint
      5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    7. Supports FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read. · PMA: P220023

      Locator
      results[0].ao_statement, fragment 2 of 2
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-07
      Source state
      Current
      Version fingerprint
      5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    8. Supports FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it. · PMA: P220026

      Locator
      results[0].pma_number
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-17
      Source state
      Current
      Version fingerprint
      d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    9. Supports FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it. · PMA: P220026

      Locator
      results[0].applicant
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-17
      Source state
      Current
      Version fingerprint
      d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    10. Supports FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it. · PMA: P220026

      Locator
      results[0].decision_date
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-17
      Source state
      Current
      Version fingerprint
      d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    11. Supports FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it. · PMA: P220026

      Locator
      results[0].decision_code
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-17
      Source state
      Current
      Version fingerprint
      d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    12. Supports FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it. · PMA: P220026

      Locator
      results[0].product_code
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-17
      Source state
      Current
      Version fingerprint
      d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    13. Supports FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it. · PMA: P220026

      Locator
      results[0].ao_statement, fragment 1 of 2
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-17
      Source state
      Current
      Version fingerprint
      d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    14. Supports FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it. · PMA: P220026

      Locator
      results[0].ao_statement, fragment 2 of 2
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2023-11-17
      Source state
      Current
      Version fingerprint
      d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.

Context Renal denervation ablation catheters as classified by the US FDA under product code QYI

Recipient
No clinical recipient
Population
Not applicable: the classification record describes a device type, not a patient group.
Care setting
Not stated in the classification record
Geography
United States (FDA device classification record)
Life stage
Not applicable
Follow-up
Not applicable (regulatory classification)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    The openFDA device classification for product code QYI names the device type ablation catheter, renal denervation, in class 3, and defines it as for denervating the renal nerves to lower blood pressure.

    Applies to No clinical recipient Renal denervation ablation catheters as classified by the US FDA under product code QYI

    Certainty method
    Not assessed
    Limitations
    A regulatory classification, not a finding about benefit or safety. The record gives no regulation number and no device description beyond its one-line definition. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Supports openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09. · FDA product code: QYI

      Locator
      results[0].product_code
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2026-11-09
      Source state
      Current
      Version fingerprint
      dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository.
    2. Supports openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09. · FDA product code: QYI

      Locator
      results[0].device_name
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2026-11-09
      Source state
      Current
      Version fingerprint
      dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository.
    3. Supports openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09. · FDA product code: QYI

      Locator
      results[0].device_class
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2026-11-09
      Source state
      Current
      Version fingerprint
      dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository.
    4. Supports openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09. · FDA product code: QYI

      Locator
      results[0].definition
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2026-11-09
      Source state
      Current
      Version fingerprint
      dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:renal-denervation-system
Content hash
85744aaf1fd3fc494ec00b5215c40d347a0852ba1777f139857afd2d1b2681a3